SCHEMBL3019028

SCHEMBL3019028

CCc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(F)ccc4C)CC3)n2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 5/20 0.36
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
MAPK1 P28482 3/20 0.34
HTR7 P34969 1/20 0.34
SMN1; SMN2 Q16637 4/20 0.34
LMNA P02545 2/20 0.34
MAPT P10636 2/20 0.34
HTT P42858 2/20 0.34
CTSS P25774 2/20 0.34
HRH3 Q9Y5N1 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TP53 P04637 1/20 0.33
GAA P10253 1/20 0.33
DNM1L O00429 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.33
MCOLN3 Q8TDD5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011191 0.94 NAAA (0.36) NAAACNR1CNR2MAPK1SMN1; SMN2
SCHEMBL3007726 0.93 NAAA (0.35) NAAACNR1CNR2MAPK1SMN1; SMN2
SCHEMBL3012974 0.92 MAPT (0.38) NAAAMAPK1SMN1; SMN2LMNAMAPT
SCHEMBL3016809 0.92 NAAA (0.40) NAAAMAPK1SMN1; SMN2LMNACTSS
SCHEMBL3018837 0.92 NAAA (0.35) NAAACNR1CNR2MAPK1SMN1; SMN2
SCHEMBL3015041 0.91 NAAA (0.36) NAAACNR1CNR2MAPK1SMN1; SMN2
SCHEMBL3009935 0.91 MAPT (0.35) NAAACNR2MAPK1SMN1; SMN2LMNA
SCHEMBL3014084 0.90 RAB9A (0.38) NAAAMAPK1SMN1; SMN2LMNAMAPT
SCHEMBL3009006 0.90 SMN1; SMN2 (0.37) NAAACNR1CNR2MAPK1SMN1; SMN2
SCHEMBL3003779 0.90 NAAA (0.35) NAAACNR1CNR2MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA NAAA 3229/4885CNR1 3069/4885CNR2 2911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.